Is it a fibroadenoma or a benign phyllodes tumour?

Andrew Lee Nottingham University Hospitals City Hospital Campus









#### Phyllodes tumour v fibroadenoma

#### Stroma

- Cellularity
- Nuclear pleomorphism
- Stromal overgrowth (x5 field with no glands)
- Mitotic rate
- Leaf-like architecture
- Irregular edge











**Fibroepithelial lesion** Partly infiltrative edge Leaf-like architecture A little stromal overgrowth Moderate/marked increase in stromal cellularity Mild/moderate stromal atypia 12 mitoses/10 high power fields **Conclusion: borderline phyllodes tumour** 











**Fibroepithelial lesion Circumscribed edge** Leaf-like areas High proportion of stroma **Increased stromal cellularity** Focal area resembling fibroadenoma Mild atypia (moderate in other sections) Mitoses 3/10 high power fields **Conclusion: benign phyllodes** 







Fibroepithelial lesion Circumscribed Leaf-like architecture No increase in stromal cellularity No atypia or mitoses Conclusion: fibroadenoma





**Fibroepithelial lesion** Circumscribed Pericanalicular Stromal expansion, but no overgrowth Moderate/marked increase in stromal cellularity **Conclusion: benign phyllodes tumour** 

### Juvenile fibroadenoma

- May be large
- May grow rapidly
- Pericannalicular
- Stromal cellularity mildly increased
- Rarely stromal overgrowth
- Epithelial hyperplasia of usual type
- Occasional mitoses may be present





#### **Benign phyllodes tumour**

- A key feature is increased stromal cellularity
- A leaf-like architecture is usually present (and can be seen in fibroadenoma)
- The following are often absent
- Nuclear pleomorphism
- Stromal overgrowth
- High mitotic count

The margin is circumscribed

#### **Diagnosis of benign phyllodes tumour**

- No single feature can be relied on
- The more features present the more likely the diagnosis (increased stromal cellularity, leaflike architecture, nuclear pleomorphism, stromal overgrowth, mitoses)
- Immunohistochemistry no value

## Benign phyllodes v fibroadenoma

- Poor reproducibility of diagnosis at the margin between these entities
- Pathol Oncol Res 2006;12:216
- Int J Surg Pathol 2014;22:695
- Where there is uncertainty WHO recommends categorisation as fibroadenoma

## Sampling

- Heterogeneity is common
- If uncertain consider taking more blocks

### Genetics

#### **MED12** mutations

- Phyllodes tumours 70 80%
- Common in fibroadenoma esp intracanalicular
- Most often missense mutations in codon 44
- **TERT promotor mutations**
- Phyllodes tumours 50 60%
- Fibroadenoma 0 7%

Mutations in cancer driver genes TP3, RB1, EGFR etc

Restricted to borderline and malignant phyllodes

Grade of local recurrences				
Original tumour	<b>Recurrent tumour</b>	Number		
Benign	Benign	27		
Benign	Borderline	17		
Benign	Malignant	4		
Borderline	Borderline	10		
Borderline	Malignant	2		
Borderline	Benign	4		
Malignant	Malignant	9		
Total 73 (Tan J Cli	n Pathol 2012;65:69			

# Wait and see approach for incompletely excised benign phyllodes tumours

- Many phyllodes tumours not diagnosed preoperatively
- As a result incomplete excision common
- Local recurrence not inevitable
- Most recurrences benign
- Wait and see approach is an option if benign
- NOT appropriate for borderline and malignant
- Eur J Cancer 1992;28:654

Distinction of cellular fibroadenoma and benign phyllodes tumour

- Does it matter?
- No studies of wait and see policy of lesions that are difficult to classify
- Need large prospective studies with central review
- Is the diagnosis of borderline and malignant phyllodes more important?

## **WHO grading**

	Benign	Borderline	Malignant
Border	Well-defined	Well-defined (focal infiltration)	Infiltrative
Stroma:			
Cellularity	Mild	Moderate	Marked
Atypia	Mild/none	Mild/moderate	Marked
Mitoses	<5	5 to 9	>10
(10 hpf, 0.196	mm²)		
Overgrowth	No	No/very focal	Often

## **Phyllodes grading**

- Not all tumours fall neatly into one of three WHO categories.
- More flexible systems eg Nottingham (Moffat 1995)
- Should each feature be given equal weight?
- Some evidence that stromal overgrowth is a particularly important feature suggesting malignant behaviour
- Lack of objective criteria for cellularity and atypia
- Wide variation of the proportion of benign, borderline and malignant phyllodes tumours in different series.
- Numerous biological markers have been shown to correlate with histological grade, but they are not of use in routine practice (reviewed in Karim J Clin Pathol 2013)

## **Benign phyllodes tumours**

- Pushing margin > 90%
- Stromal overgrowth +/++
- Cellularity +/++
- Nuclear pleomorphism +/++
- Mitoses <10/10hpf (0.152 mm<sup>2</sup>)
- If four features present = benign Moffat Histopathology 1995;27:205-18

## Malignant phyllodes tumour

- Infiltrative margin > 50%
- Stromal overgrowth ++/+++
- Cellularity ++/+++
- Nuclear pleomorphism ++/+++
- Mitoses >10/10hpf (0.152 mm<sup>2</sup>)
- If four features present = malignant
- Necrosis & heterologous elements only seen malignant
  Moffat Histopathology 1995;27:205-18

## **Fibroepithelial lesions**

Value of preoperative diagnosis

- Fibroadenoma usually need not be excised
- Phyllodes tumour excise
- Hamartoma need not be excised

# Excision diagnosis after core showing cellular fibroepithelial lesion

**Proportion of phyllodes tumours** 5/32 (16%) El-Sayed et al. 2008 19/52 (37%) Rakha et al. 2011 12/29 (41%) Jacobs et al. 2005 25/57 (44%) Komenaka et al. 2003 11/16 (69%) Rakha et al. 2011 10/14 (71%) Bode et al. 2007 36/50 (72%) Lee et al. 2007 39/51 (76%) Abdulcadir et al. 2014

Studies of fibroadenoma v phyllodes tumour on core biopsy **Cellular fibroepithelial lesions on core** Jacobs et al. Am J Clin Pathol 2005;124:342 Resetkova et al. Breast J 2010;6:573 Jara-Lazaro et al. Histopathology 2010;57:220 Excision diagnosis then look at core Lee et al. Histopathology 2007;51:336 Morgan et al. Histopathology 2010;56:489 Tsang et al. Histopathology 2011;59:600























**Features favouring** phyllodes on core biopsy Consistently of value in different studies **Stromal cellularity** Stromal overgrowth (x10 field with no epithelium) Stromal mitoses (3 or more/10hpf) Marked stromal pleomorphism **Fragmentation** Of value in only some studies Irregular edge **Entrapped fat** Increased stromal cellularity adjacent to epithelium Absence of epithelial hyperplasia **Consistently NOT of value** Intracanalicular growth pattern/leaf-like architecture

## Features favouring phyllodes on core biopsy

Most not completely specific Best used in combination (further research needed)

κ > 0.6 (Histopathology 2007;51:136)
Stromal cellularity (mild increase in 50%+)
Stromal overgrowth (x10 field with no epithelium)
Fragmentation

#### False-negative core biopsy (excision = phyllodes previous core = fibroadenoma etc)

- Tsang 2011
- Bode 2007
- Choi 2012
- Lee 2007
- Foxcroft 2007
- Guillot 2011
- Youn 2013
- Dillon 2006

3/49 (7%) 2/12 (17%) 25/129 (19%) 11/44 (25%) 5/17 (29%) 16/54 (30%) 54/168 (32%) 9/23 (39%)

 Reasons: heterogeneity, missed lesion, occasionally diagnostic error

### Core = fibroadenoma Excision = phyllodes

- BUT < 1% of lesions called fibroadenoma on core are later found to be phyllodes
- Balance between sensitivity of diagnosis of phyllodes and too low a threshold for reporting minor changes
  Breast 2007;16:27 Surgery 2006;140:779 Histopathology 2007;51:136 Acta Radiol 2007;48:708

## **B3 cellular fibroepithelial lesion**

Repeat core biopsy not useful

## **Fibroepithelial lesions**

Indications for excision

- Phyllodes in differential on core
- Size 30mm+
- Growing
- Ultrasound shows septae
- Patient wishes
- Age ? of value

Breast 2007;16:27 Surgery 2006;140:779 Histopathology 2007;51:136